Article

Assessment of the inter-individual variation observed between patients receiving HIV antiretroviral therapy

2018-01-01

Abstract excerpt

The WHO currently recommends tenofovir (TFV) disoproxil fumarate (TDF) or TFV alafenamide (TAF) as a preferred first-line antiretroviral therapy (ART) for the treatment and prevention of HIV. However, mild to moderate TFV-related renal toxicity is an uncommon but significant complication for TDF therapy. Efavirenz (EFV) is also approved for first line treatment, with the approval of a lower dose treatment, 600mg t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 99f667f8-8481-5b5c-8ace-25385993e445
DOI: 10.17638/03027990

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Assessment of the inter-individual variation observed between patients receiving HIV antiretroviral therapyDOI 10.17638/03027990Read

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read

Determinants of anti-retroviral therapy drug-related toxicities in HIV positive patientsSemantic proximity Read

Pharmacogenetics of Tenofovir TreatmentSemantic proximity Read

Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.Semantic proximity Read

A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.Semantic proximity Read

Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Semantic proximity Read

Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Semantic proximity Read

Pharmacogenomics of Antiretroviral Drug Metabolism and TransportSemantic proximity Read

Clinical impact of patient population differences and genomic variation in efavirenz therapySemantic proximity Read

Investigation of molecular mechanisms regulating drug-drug interactions in antiretroviral therapySemantic proximity Read

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.Semantic proximity Read